Company intelligence / Profile preview

Paganella

Wayne, Pennsylvania, United Statespaganella.net ↗

Ownership: Private
Development stage: Preclinical

Overview

Lead product QTORIN™ rapamycin is in Phase 3 SELVA trial for microcystic lymphatic malformations and Phase 2 TOIVA trial for cutaneous venous malformations. The product has received Breakthrough Therapy Designation, Orphan Drug Designation, and Fast Track Designation from the FDA for microcystic LMs.

Therapeutic areas: DermatologyRare Diseases
Modalities: Small moleculesTopical formulations
Industry: Biotech

Drug pipeline

1 asset

navitoclax

Pre-clinical

Indications: Cellular senescence, Endothelial dysfunction

Partnerships

MedPharm LtdPieris Pharmaceuticals, Inc.

Beyond the preview

Go deeper on Paganella.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Paganella.

Explore the full profile